Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Humanized anti-CD117 Monoclonal Antibody (JSP191)
Humanized anti-CD117 Monoclonal Antibody · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Blood Stem Cell Transplant w/ anti-CD117 conditioning | EXPERIMENTAL | The phase 1a portion of the study plans to assess approximately 3 planned dose cohorts of JSP191: 0.3 mg/kg, 0.6 mg/kg, and 1.0 mg/kg to determine the maximum tolerated dose for expansion. Subjects will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery. The phase 1b portion of the study will enroll additional subjects at the expansion dose in order to further explore the safety, feasibility, and PK of that dose. |
| Name | Type | Description |
|---|---|---|
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | BIOLOGICAL | Procedure: single intravenous infusion of JSP191 antibody |
Key Inclusion Criteria: * AML/MDS as defined by specific criteria, including but not limited to the following subtypes: 1. AML in CR 2. MDS \< 5% BM blasts 3. MDS 5 - 10% BM blasts 4. AML not in CR or MDS \> 10% BM blasts * Patients with human leukocyte antigen (HLA) matched related or unr...
Top 20 of 32 competitors